GHK-Cu

The controlled literature is dominated by in-vitro and rodent work: activity has been studied in cultured human fibroblasts and keratinocytes, in gene-expression profiling, and in rodent models of skin and connective-tissue repair, with a substantial review literature framing it as a modulator of cellular pathways in skin regeneration. Roughly 80 records exist under this name and about 25 under copper tripeptide, and the majority are mechanistic, review or cosmetic-science articles rather than controlled clinical studies. Verified controlled human interventional evidence is essentially absent: the one registered study specific to the compound is a phase 2 randomised study of a topical gel against vehicle in 60 estimated participants, which began recruiting on 2 February 2026 and has posted no results. Remaining human context is observational, since the tripeptide is present endogenously in plasma.

What is not established

No completed controlled human study with published results was identified for any indication or route. The FDA states there are limited human data to inform safety considerations for injectable use, and flags aggregation and peptide-related impurities as the specific unresolved quality questions for that route.

What distinguishes GHK-Cu

It is not a pure peptide but a metal-coordination complex: a three-residue peptide chelating a copper ion, which makes copper content and copper speciation quality attributes that simply do not exist for the other compounds here. At three residues it is by far the shortest, against fifteen, sixteen and thirty-seven for its neighbours. Commercially the decisive fact is the split in its regulatory identity: it holds a settled cosmetic-ingredient position while having no medicinal authorisation anywhere, and its FDA listing is uniquely qualified for injectable routes, where the entries for the others carry no route limitation.

Sources

1. US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks, GHK-Cu entry, injectable routes
2. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987
3. Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108
4. ClinicalTrials.gov. NCT07437586, phase 2 randomised study of a topical gel against vehicle, recruiting from 2 February 2026
5. World Anti-Doping Agency. 2026 Prohibited List, searched in full with no occurrence of GHK, GHK-Cu or copper tripeptide

This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.